Verastem (NASDAQ:VSTM – Free Report) had its target price trimmed by Alliance Global Partners from $34.00 to $20.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on VSTM. Royal Bank of Canada […]